# SANTA CRUZ BIOTECHNOLOGY, INC.

# p-ERα (Ser 106): sc-101674



## BACKGROUND

Estrogen receptor  $\alpha$  (ER $\alpha$ , ER, ESR, ESRA, Era, NR3A1, estrogen receptor 1) is a ligand-activated transcription factor composed of several domains important for hormone binding, DNA binding and activation of transcription. Alternative splicing results in several ER $\alpha$  mRNA transcripts, which differ primarily in their 5' untranslated regions. ER $\alpha$  undergoes phosphorylation in response to estradiol binding. Human ER $\alpha$  is predominately phosphorylated on Ser 118 and, to a lesser extent, on Ser 104 and Ser 106. In response to activation of the mitogen-activated protein kinase pathway, phosphorylation occurs on Ser 118 and Ser 167. These serine residues are all located within the activation function 1 region of the N-terminal domain of ER $\alpha$ . In contrast, activation of protein kinase A increases the phosphorylation of Ser 236, which is located in the DNA-binding domain. Src kinase-dependent Tyr 537 phosphorylation may enhance estrogen binding to ER $\alpha$ . Mutation of Tyr 537 of the human ER $\alpha$  produces receptors having a range of constitutive activity.

## REFERENCES

- Arnold, S.F., et al. 1995. Phosphorylation of Tyrosine 537 on the human estrogen receptor is required for binding to an estrogen response element. J. Biol. Chem. 270: 30205-30212.
- Weis, K.E., et al. 1996. Constitutively active human estrogen receptors containing amino acid substitutions for Tyrosine 537 in the receptor protein. Mol. Endocrinol. 10: 1388-1398.
- Arnold, S.F., et al. 1997. Estradiol-binding mechanism and binding capacity of the human estrogen receptor is regulated by tyrosine phosphorylation. Mol. Endocrinol. 11: 48-53.
- Joel, P.B., et al. 1998. pp90 Rsk-1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser 167. Mol. Cell. Biol. 18: 1978-1984.

#### CHROMOSOMAL LOCATION

Genetic locus: ESR1 (human) mapping to 6q25.1; Esr1 (mouse) mapping to 10 A1.

#### SOURCE

p-ER $\alpha$  (Ser 106) is a rabbit polyclonal antibody raised against a short amino acid sequence containing Ser 106 phosphorylated ER $\alpha$  of human origin.

#### PRODUCT

Each vial contains 100  $\mu g$  IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

## **STORAGE**

Store at 4° C, \*\*D0 NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

## **RESEARCH USE**

For research use only, not for use in diagnostic procedures.

#### APPLICATIONS

p-ER $\alpha$  (Ser 106) is recommended for detection of Ser 106 phosphorylated ER $\alpha$  of human origin and correspondingly phosphorylated Ser 110 of mouse origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence and immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500).

Suitable for use as control antibody for ER $\alpha$  siRNA (h): sc-29305, ER $\alpha$  siRNA (m): sc-29306, ER $\alpha$  shRNA Plasmid (h): sc-29305-SH, ER $\alpha$  shRNA Plasmid (m): sc-29306-SH, ER $\alpha$  shRNA (h) Lentiviral Particles: sc-29305-V and ER $\alpha$  shRNA (m) Lentiviral Particles: sc-29306-V.

Molecular Weight of p-ER $\alpha$  long isoform: 66 kDa.


Molecular Weight of p-ER $\alpha$  short isoform: 54 kDa.


Molecular Weight of ER46: 48 kDa.

Molecular Weight of ER36: 36 kDa.

Positive Controls: MCF7 whole cell lysate: sc-2206.

#### DATA





p-ER $\alpha$  (Ser 106): sc-101674. Western blot analysis of phosphorylated ER $\alpha$  expression in untreated (**A**) and estradiol-treated (**B**) MCF7 whole cell lysates.

 $p\text{-}ER\alpha$  (Ser 106): sc-101674. Immunoperoxidase staining of formalin-fixed, paraffin-embedded human breast carcinoma tissue showing nuclear localization.

## SELECT PRODUCT CITATIONS

 Wang, Y.C., et al. 2011. Estrogen suppresses metastasis in rat hepatocellular carcinoma through decreasing interleukin-6 and hepatocyte growth factor expression. Inflammation 35: 143-149.

#### **PROTOCOLS**

See our web site at www.scbt.com or our catalog for detailed protocols and support products.